| Document |
Document Title |
|
WO/2016/153263A2 |
The present invention relates to: a method for producing a spheroid form of tonsil-derived stem cells, the method enhancing growth and differentiation efficiency of tonsil-derived stem cells; and a method for producing a spheroid form of...
|
|
WO/2016/151300A1 |
Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes, are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of sec...
|
|
WO/2016/154580A1 |
The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.
|
|
WO/2016/146812A2 |
The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.
|
|
WO/2016/145982A1 |
Disclosed is a use of carnosic acid in preparing a composition used to prevent or treat diabetes, diabetic nephropathy, hyperlipidemia, or non-alcoholic fatty liver, and a use of a rosemary petroleum ether extract in preparing a composit...
|
|
WO/2016/145622A1 |
The present invention belongs to the technical field of the pharmaceutical chemistry. Disclosed specifically are benzimidazole derivatives, a preparation method therefor and a medicinal use thereof. The benzimidazole derivatives comprise...
|
|
WO/2016/145983A1 |
A use of an isoquinoline alkaloid in preparing a composition used to treat or prevent diabetes, diabetic nephropathy, hyperlipidemia, and non-alcoholic fatty liver. The isoquinoline alkaloid is phellodendrine or a pharmaceutical salt, hy...
|
|
WO/2016/145935A1 |
Provided is a series of new poly-fluorosubstituted pyrazolopyrimidine compounds or salts. The compounds are Bruton's tyrosine kinase (BTK) inhibitors. The compounds have better kinase inhibition selectivity and pharmokinetic properties. ...
|
|
WO/2016/145532A1 |
Described are methods and uses for treating or preventing fatty liver disease. Also provided are methods and uses for the treatment or prevention of insulin resistance. Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) is shown to p...
|
|
WO/2015/071657A9 |
Described herein are certain steroid derivative compounds, for example of formula (I): wherein X1, X2, X3 L, and Ar are as defined herein, pharmaceutical compositions comprising such compounds, the use of such compounds and compositions ...
|
|
WO/2016/141774A1 |
Uses of Jilin ginseng oligopeptide in preparing a food product or healthcare food product for improving and enhancing sexual function.
|
|
WO/2016/141139A1 |
A method for preparing a standardized Wedelia chinensis extract and an extract prepared by the method. Also provided is a method for qualifying the standardized extract by characterizing its most abundant compounds and its biological act...
|
|
WO/2016/138631A1 |
Compounds of formula I and the pharmaceutically acceptable salt thereof are disclosed, wherein R is selected from the group consisting of O and NH, R 1 is selected from the group consisting of CF 3, OCF 3 and Cl.
|
|
WO/2016/136849A1 |
Provided are: a solid preparation which improves the stability of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-6-yl)phenyl)-N'-methoxyure
a and a...
|
|
WO/2016/136933A1 |
A pharmaceutical composition for treating IL-6-related diseases having as an active ingredient an IL-6 inhibitor, wherein the pharmaceutical composition is administered as usual after a short-interval dosing period where the same dose as...
|
|
WO/2016/134174A1 |
. Novel methods of improving or enhancing psychological, somatic, and sexual conditions in an aging male human subject, by administering fenugreek or fenugreek seeds, or an extract of fenugreek or fenugreek seeds, are described. Novel me...
|
|
WO/2016/127948A1 |
Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases su...
|
|
WO/2016/127916A1 |
This application relates to a substituted amino six-membered saturated heterocyclic fat, used as a long-acting DPP-IV inhibitor, as represented by the general formula I, a method for preparing same, a pharmaceutical combination thereof, ...
|
|
WO/2016/127342A1 |
The present invention provides use of chlorogenic acid in preparation of a medicine for treating progeria. Chlorogenic acid can effectively treat progeria. Compared with a positive medicine namely rapamycin, the chlorogenic acid has a su...
|
|
WO/2016/131049A1 |
A method for one of preventing and minimizing diabetes pathology in a mammal, comprising administering to the mammal an effective amount of N- acetylcysteine (NAC).
|
|
WO/2016/127749A1 |
A lactic acid bacteria fermented flour, comprising: protein, a total amount of sugar, total phenol, a total amount of dietary fiber, and β-glucan. The lactic acid bacteria fermented flour is prepared through the following steps: milling...
|
|
WO/2016/124149A1 |
Provided are a new crystalline form of an antiandrogen drug which treats prostate cancer, said drug being represented by formula I, and a preparation method for the new crystalline form. The crystalline form has good stability, and the s...
|
|
WO/2016/120821A1 |
The present invention relates to a process for providing the compound of formula I, comprising the step of reacting a compound of formula VII with a base in the presence of an alkaline- or alkaline earth metal salt (MX), wherein LG is a ...
|
|
WO/2016/119856A1 |
The present invention relates to the use of autophagy-inducing molecules for increasing release or secretion of insulin by pancreatic β cells. It is useful for treating hyperglycemia, associated or not with diabetes.
|
|
WO/2016/118611A1 |
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...
|
|
WO/2016/117654A1 |
Provided is an early insulin secretion promoter. An early insulin secretion promoter having as an active ingredient a composition containing 1 × 1010 cells or more of live lactic acid bacteria.
|
|
WO/2016/113635A1 |
The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non¬ alcoholic steatohepatitis (NASH) and their sequelae by administrat...
|
|
WO/2016/107603A1 |
The present invention relates to a compound of formula (V), preparation method therefor and pharmaceutical applications thereof. Specifically, the present invention relates to derivatives represented by the general formula (V), preparati...
|
|
WO/2016/108237A1 |
Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic β-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secre...
|
|
WO/2016/109155A1 |
Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25- dihydroxyvitamin D3 (2MD) to treat primary hyperparathyroidism or the symptoms of primary hyperparathyroidism in a subject in need thereof. Also disclosed are method...
|
|
WO/2016/109492A1 |
The present invention provides compounds having the general structural formula (I) [formula should be inserted here] and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and ad...
|
|
WO/2016/102775A1 |
The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or ...
|
|
WO/2016/102776A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prev...
|
|
WO/2016/099495A1 |
The current invention relates to methods of reducing hyperthyroidism in an animal by feeding the animal with a diet including vitamin K. The vitamin K is in an amount effective to reduce factors such as creatinine, triiodothyronine (T3),...
|
|
WO/2016/097108A1 |
The invention relates to a derivative of a GLP-1 analogue of a general Formula I, which derivative comprises a side chain attached to a Lys residue at position 34, 35, 36, 37, 38, or 39 of the GLP-1 analogue. The side chain comprises a B...
|
|
WO/2016/093637A1 |
The present invention relates to a composition for preventing and improving andropause, comprising a carob extract as an active ingredient. Thereby, the present invention can improve symptoms which appear in men with andropause, such as ...
|
|
WO/2016/093362A1 |
Artificial tissue containing pancreatic islet cells, fibroblasts and/or cells having the ability to differentiate, extracellular matrix, and vascular endothelial cells, in which: the fibroblasts and/or cells having the ability to differe...
|
|
WO/2016/087352A1 |
The invention relates to a compound of formula (I) wherein A1, A2 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2016/087810A1 |
This invention relates to the use of a plant extract, derived from a Salvia spp, comprising one or more tanshinone compounds, or said one or more tanshinone compounds, in the treatment of wounds, particularly chronic wounds, or other con...
|
|
WO/2016/084956A1 |
Provided is a means with which it is possible to efficiently prevent or improve symptoms triggered by an imbalance of sex hormones with as little pain as possible, and which can safely be taken daily. A compound selected from the group c...
|
|
WO/2016/084816A1 |
Provided is a bicyclic compound having an inhibitory effect on acetyl-CoA carboxylase. A compound represented by the formula: (in the formula, each of the symbols is as defined in the specification) or a salt thereof has an inhibitory ef...
|
|
WO/2016/084412A1 |
It is found that the activation of a B cell can be inhibited by TGF-beta3 produced by LAG3+ Treg. A B cell activation inhibitor comprising TGF-beta3 or a molecule having the function of TGF-beta3 and a therapeutic agent for autoimmune di...
|
|
WO/2016/080533A1 |
Provided is a novel means for administrating cinacalcet or a pharmaceutically acceptable salt thereof, said means being capable of exhibiting excellent pharmacological effects while avoiding side effects which may be caused by oral admin...
|
|
WO/2016/079302A1 |
The present invention relates a pharmaceutical formulation comprising a long-acting growth hormone for use in a method of treating growth hormone deficiency, wherein the long-acting growth hormone formulation is administered to a patient...
|
|
WO/2016/074566A1 |
Disclosed are a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, an easily-hydrolytic prodrug ester thereof or an isomer thereof, and a pharmaceutical composition containing the compound used as a ...
|
|
WO/2016/077620A1 |
The present invention refers to a GPR101 inhibitor, antagonist or inverse agonist or inverse agonist for use in preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism and to met...
|
|
WO/2016/072871A1 |
The invention relates to the Proline-Rich Polypeptide complex (PRP) derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurotrophic Factor level a...
|
|
WO/2016/070798A1 |
Provided in the present invention is a use of endostatin or a functional variant thereof in the preparation of a drug for treating alimentary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In an em...
|
|
WO/2016/066668A1 |
A pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt thereof in combination with a PPAR dual agonist or a pharmaceutically acceptable salt thereof.
|
|
WO/2016/066662A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R10, R11, R12, R13, R14, R15, R16, R17 and m are as described herein, compositions including the compounds and methods of using...
|
